Accuray Incorporated (NASDAQ: ARAY) experienced a notable recovery during the latest extended trading session, with its stock climbing by 5.26% to reach $2.60. This rebound completely nullified the 4.26% loss incurred during the regular trading hours, closing at $2.47. ARAY’s forthcoming participation in a notable event planned for the subsequent week was mentioned as the cause of the increase in ARAY stocks.
Accuray (ARAY) is slated to partake in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference set for February 13, 2024. It’s crucial to note that BTIG-sponsored gatherings are exclusively for BTIG patrons, past and present.
Accuray also revealed recently that the Providence Swedish Radiosurgery Center in Seattle, Washington, is strengthening its capacity to treat cancer by acquiring the most modern CyberKnife S7 System. The hospital has now invested in the CyberKnife radiation delivery equipment twice thanks to this acquisition.
Due to its robotic structure, ensuring unparalleled precision and accuracy, the apparatus is also an excellent choice for addressing neurological issues. With this advanced technology, healthcare professionals can deliver top-tier stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) treatments more rapidly, expanding access to effective and efficient treatment options for a greater number of patients.
Since adopting their initial CyberKnife System over a decade ago, the Providence Swedish Radiosurgery Center and Accuray have cultivated a strong partnership. This collaboration aims to enhance the cancer patient journey by employing cutting-edge technologies that extend survival and enhance post-treatment quality of life, all while enhancing patient comfort.
The center’s continued support of Accuray technology demonstrates their faith in the business and its line of goods. The Providence Swedish Radiosurgery Center has made notable contributions to radiation medicine, including pioneering a large multi-center clinical trial assessing SBRT in prostate cancer using the CyberKnife System. They continue to lead research efforts exploring SBRT’s efficacy in treating tumors in various body regions and utilizing radiosurgery for cancer and neurological conditions.
